

Contact: Nadia Repenning
Location: Boulder, CO

Email: nadia@agentsheets.com

Tel: 303-530-1773

Website: www.agentsheets.com





National Institutes of Health Commercialization Assistance Program (NIH-CAP)

Company Overview

Industry Sector: Education

Company Overview: AgentSheets Inc., is a leading provider of K–12 educational authoring environments based on interactive, collaborative game design and tailored to computational science and IT standards.

Target Market(s): K-12 education worldwide.

Key Value Drivers

Technology*: AgentSheets, Inc. creates engaging discovery-oriented simulation technology that helps users understand interdependent complex systems. This framework, Collective Simulations, creates extraordinary immersive learning experiences that are discovery-oriented and consistent with curriculum covering interdependent complex systems.

Competitive Advantage: Mr. Vetro is the only education tool that teaches K–12 children human physiology through an engaging networked cyberlearning system that structures the human body into decoupled subsystems with little if any connections between the organs.

Plan & Strategy: - Seeking strategic partners

- Expanding coverage of curriculum through funding

*Technology funded by the NCRR and being commercialized under the NIH-CAP

Management

Leadership:

Nadia Repenning, President and CEO Alexander Repenning, Chief Technology Officer Robert Owen, Vice President Technical Development

Scientific Advisory Board:

Dr. David Webb, Associate Professor, University of Colorado, School of Education and Executive Director, Freudenthal Institute
Dr. Christof Daetwyler, Research Assistant Professor, Office of Educational Affairs, Technology in Medical Education (TIME) and Clinical Skills and Clinical Skills Assessment

Product Development

AgentSheets Educational Tools

Established Internet-based sales plus direct sales to individual school districts, teachers and students.

Mr. Vetro

AgentSheets educational tool based technology.

Phase A: Research and evaluation, SBIR phases I + II

Phase B: Commercialization; developing joint ventures with potential commercialization partners.